Stewart Carly, Garcia-Filion Pamela, Fink Cassandra, Ryabets-Lienhard Anna, Geffner Mitchell E, Borchert Mark
The Vision Center, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027 USA.
Division of Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027 USA.
Int J Pediatr Endocrinol. 2016;2016:5. doi: 10.1186/s13633-016-0023-9. Epub 2016 Mar 2.
Hypopituitarism and obesity are causes of major lifelong morbidity in patients with optic nerve hypoplasia (ONH). Growth hormone deficiency (GHD) affects the majority of children with ONH, though the degree of deficiency and variability of early growth patterns range from early severe retardation to normal initial growth. The utility of early GH replacement for improving anthropometric, body composition, and lipid outcomes in patients with ONH and GHD, especially those with normal initial height velocity, is unknown. This study examines the effects of GH replacement in a cohort of children with ONH and GHD.
Controlled clinical trial from 2005-2014. The study included 17 children with ONH and untreated GHD. Those meeting criteria for growth deceleration were assigned to treatment with recombinant human growth hormone (n = 5) while those with normal height velocity were randomized either to treatment (n = 5) or to observation (no intervention, n = 7). Study duration was 3 years. Primary outcome measures included stature, weight, weight-for-stature, and BMI standard deviation score (SDS) at study completion.
Subjects on GH, irrespective of entry growth trajectory, grew more on average in stature than controls by a difference of 0.98 SDS by study end; this effect persisted after adjusting for baseline overweight status. Treatment had an effect on weight SDS only after adjusting for initial overweight status, resulting in an average increase of 0.83 SDS more than controls. Subjects who were overweight at the outset experienced greater gains in both weight and stature SDS. Treatment had no statistically significant impact on weight-for-stature or BMI SDS. A reduction in body fat percentage was observed in those treated, both before (-6.1 %) and after (-4.3 %) adjustment for initial overweight status.
Early GH replacement has a positive effect on short-term statural outcomes in children with ONH and GHD, even in those exhibiting normal initial linear growth. Results were less conclusive regarding treatment effects on body composition and lipids.
垂体功能减退和肥胖是视神经发育不全(ONH)患者终生发病的主要原因。生长激素缺乏症(GHD)影响大多数患有ONH的儿童,尽管缺乏程度和早期生长模式的变异性范围从早期严重发育迟缓到正常的初始生长。早期生长激素替代疗法对改善ONH和GHD患者的人体测量、身体成分和脂质结果的效用尚不清楚,尤其是那些初始身高增长速度正常的患者。本研究调查了生长激素替代疗法对一组ONH和GHD儿童的影响。
2005年至2014年的对照临床试验。该研究纳入了17名患有ONH和未经治疗的GHD的儿童。那些符合生长减速标准的儿童被分配接受重组人生长激素治疗(n = 5),而那些身高增长速度正常的儿童被随机分配接受治疗(n = 5)或观察(不干预,n = 7)。研究持续时间为3年。主要结局指标包括研究结束时的身高、体重、身高体重比和BMI标准差评分(SDS)。
接受生长激素治疗的受试者,无论初始生长轨迹如何,到研究结束时平均身高增长比对照组多0.98 SDS;在调整基线超重状态后,这种效果仍然存在。仅在调整初始超重状态后,治疗对体重SDS有影响,导致平均比对照组增加0.83 SDS。一开始超重的受试者在体重和身高SDS方面的增加更大。治疗对身高体重比或BMI SDS没有统计学上的显著影响。在调整初始超重状态之前(-6.1%)和之后(-4.3%),接受治疗的受试者的体脂百分比均有所下降。
早期生长激素替代疗法对患有ONH和GHD的儿童的短期身高结局有积极影响,即使是那些初始线性生长正常的儿童。关于治疗对身体成分和脂质的影响,结果不太确凿。